Printer Friendly

DANIEL I.C. WANG, PH.D., JOINS ALTUS SCIENTIFIC ADVISORY BOARD

 CAMBRIDGE, Mass., June 8 /PRNewswire/ -- Daniel I.C. Wang, Ph.D., has joined the Scientific Advisory Board of Altus Biologics Inc., a subsidiary of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX).
 Peter Lanciano, general manager of Altus, commented, "The addition of Dr. Wang to our Scientific Advisory Board is a significant event for Altus Biologics. His expertise in chemical engineering will be a great asset as Altus moves ahead in developing Cross-Linked Enzyme Crystals (CLECs)(tm) for specific applications. Dr. Wang has a worldwide reputation in chemical process engineering."
 Dr. Wang has spent much of his career at the Massachusetts Institute of Technology, where he directs the Biotechnology Process Engineering Center and is Chevron Professor of Chemical Engineering. He is the recipient of awards from the American Institute of Chemical Engineers and the American Chemical Society. He has also been elected to the American Academy of Arts and Sciences, the National Academy of Engineering and Academia Sinica in the Republic of China.
 Dr. Wang serves on the editorial boards of 11 publications and was editor in chief of Biotechnology and Bioengineering. He chairs the Peer Review Committee for Biotechnology of the National Academy of Engineering and serves on the National Biotechnology Policy Board of the National Institutes of Health. For the National Research Council of the National Academy of Sciences, he is on the Board of Chemical Sciences and Technology and was previously on the Board of Biology. He has co- authored five textbooks including "Fermentation and Enzyme Technology" and has authored over 150 scientific journal articles.
 A native of China, Dr. Wang was educated in the United States and received a bachelor's of science degree in chemical engineering and a master's of science degree in biochemical engineering from the Massachusetts Institute of Technology. He received a Ph.D. in chemical engineering from the University of Pennsylvania.
 Altus Biologics Inc. is a subsidiary of Vertex Pharmaceuticals Incorporated, formed in late 1992 to develop and commercialize proprietary protein stabilization technology. The first implementation of the technology is Cross-Linked Enzyme Crystals (CLECs), crystallized enzymes that have been stabilized by chemically cross-linking individual molecules. Altus' mission is to design and develop high performance biocatalysts that will be used in specialty chemical and pharmaceutical manufacturing and other enzyme-based products.
 -0- 6/8/93
 /CONTACT: Stephanie K. Marrus, corporate communications director, Vertex, 617-499-2490; or Robert Gottlieb, senior vice president, Feinstein Partners Inc., 617-577-8110, for Vertex/
 (VRTX)


CO: Altus Biologics, Inc.; Vertex Pharmaceuticals, Inc. ST: Massachusetts IN: MTC SU: PER

CM -- NE012 -- 6605 06/08/93 14:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 8, 1993
Words:421
Previous Article:ROGERS CORPORATION, AT ANNUAL MEETING, PROJECTS FIRST HALF EARNINGS TO BE HIGHEST IN RECENT YEARS
Next Article:DONALD R. CONKLIN JOINS BOARD AT CYTOTHERAPEUTICS
Topics:


Related Articles
LAWRENCE A. LOEB JOINS NEORX SCIENTIFIC ADVISORY BOARD
XOMA ANNOUNCES NEW SCIENTIFIC ADVISORY BOARD MEMBERS
EPITOPE ADDS TWO MEMBERS TO ITS SCIENTIFIC ADVISORY BOARD
ALTUS BIOLOGICS IS RECIPIENT OF 33RD ANNUAL R&D 100 AWARD FOR NOVEL CLEC TECHNOLOGY
Aptus Genomics, Inc. Appoints Members to Its Scientific Advisory Board.
/C O R R E C T I O N -- Nastech Pharmaceutical Company Inc./.
H. Lee Sweeney, Ph.D. Joins PTC Therapeutics' Scientific Advisory Board.
Transgene Sets up an International Scientific Advisory Board.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters